BGM Group Ltd. (BGM) stock
BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
$8.13+0.12 (+1.50%)
Close on Nov 17, 2026Market cap $3.26BP/E –Yield –
BGM r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $672.67K, down 50.6% from the year before. The highest annual figure on record is $1.36M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $672.67K | -50.6% |
| FY2024 | Sep 30, 2024 | $1.36M | +139.5% |
| FY2023 | Sep 30, 2023 | $568.47K | -53.6% |
| FY2022 | Sep 30, 2022 | $1.22M | +15204.3% |
| FY2021 | Sep 30, 2021 | $8.00K | -85.2% |
| FY2020 | Sep 30, 2020 | $54.00K | +22.7% |
| FY2019 | Sep 30, 2019 | $44.00K | – |
See a number that looks wrong?